Top 20 Multiple Sclerosis Drugs Market Analysis and Segment Forecasts To 2030
- Published: May, 2025
- Report ID: GVR-MT-100324
- Format: PDF/Excel databook
- No. of Pages/Datapoints: 150
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Research Methodology
1.3. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Top 20 Multiple Sclerosis Drugs Market: Product Business Analysis
3.1. Product Market Share, 2024 & 2030
3.2. Product Segment Dashboard
3.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
3.3.1. OCREVUS
3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.1.2. Impact of Generics/Biosimilars
3.3.1.3. Patent Expiry Analysis
3.3.1.4. Pricing and Reimbursement Scenario
3.3.1.5. Indication Approved
3.3.1.6. Competitive Scenario
3.3.2. TECFIDERA
3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.2.2. Impact of Generics/Biosimilars
3.3.2.3. Patent Expiry Analysis
3.3.2.4. Pricing and Reimbursement Scenario
3.3.2.5. Indication Approved
3.3.2.6. Competitive Scenario
3.3.3. VUMERITY
3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.3.2. Impact of Generics/Biosimilars
3.3.3.3. Patent Expiry Analysis
3.3.3.4. Pricing and Reimbursement Scenario
3.3.3.5. Indication Approved
3.3.3.6. Competitive Scenario
3.3.4. AVONEX
3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.4.2. Impact of Generics/Biosimilars
3.3.4.3. Patent Expiry Analysis
3.3.4.4. Pricing and Reimbursement Scenario
3.3.4.5. Indication Approved
3.3.4.6. Competitive Scenario
3.3.5. PLEGRIDY
3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.5.2. Impact of Generics/Biosimilars
3.3.5.3. Patent Expiry Analysis
3.3.5.4. Pricing and Reimbursement Scenario
3.3.5.5. Indication Approved
3.3.5.6. Competitive Scenario
3.3.6. TYSABRI
3.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.6.2. Impact of Generics/Biosimilars
3.3.6.3. Patent Expiry Analysis
3.3.6.4. Pricing and Reimbursement Scenario
3.3.6.5. Indication Approved
3.3.6.6. Competitive Scenario
3.3.7. FAMPYRA
3.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.7.2. Impact of Generics/Biosimilars
3.3.7.3. Patent Expiry Analysis
3.3.7.4. Pricing and Reimbursement Scenario
3.3.7.5. Indication Approved
3.3.7.6. Competitive Scenario
3.3.8. KESIMPTA
3.3.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.8.2. Impact of Generics/Biosimilars
3.3.8.3. Patent Expiry Analysis
3.3.8.4. Pricing and Reimbursement Scenario
3.3.8.5. Indication Approved
3.3.8.6. Competitive Scenario
3.3.9. GILENYA
3.3.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.9.2. Impact of Generics/Biosimilars
3.3.9.3. Patent Expiry Analysis
3.3.9.4. Pricing and Reimbursement Scenario
3.3.9.5. Indication Approved
3.3.9.6. Competitive Scenario
3.3.10. COPAXONE
3.3.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.10.2. Impact of Generics/Biosimilars
3.3.10.3. Patent Expiry Analysis
3.3.10.4. Pricing and Reimbursement Scenario
3.3.10.5. Indication Approved
3.3.10.6. Competitive Scenario
3.3.11. AUBAGIO
3.3.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.11.2. Impact of Generics/Biosimilars
3.3.11.3. Patent Expiry Analysis
3.3.11.4. Pricing and Reimbursement Scenario
3.3.11.5. Indication Approved
3.3.11.6. Competitive Scenario
3.3.12. MAVENCLAD
3.3.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.12.2. Impact of Generics/Biosimilars
3.3.12.3. Patent Expiry Analysis
3.3.12.4. Pricing and Reimbursement Scenario
3.3.12.5. Indication Approved
3.3.12.6. Competitive Scenario
3.3.13. Rebif
3.3.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.13.2. Impact of Generics/Biosimilars
3.3.13.3. Patent Expiry Analysis
3.3.13.4. Pricing and Reimbursement Scenario
3.3.13.5. Indication Approved
3.3.13.6. Competitive Scenario
3.3.14. AMPYRA
3.3.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.14.2. Impact of Generics/Biosimilars
3.3.14.3. Patent Expiry Analysis
3.3.14.4. Pricing and Reimbursement Scenario
3.3.14.5. Indication Approved
3.3.14.6. Competitive Scenario
3.3.15. BETASERON
3.3.15.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.15.2. Impact of Generics/Biosimilars
3.3.15.3. Patent Expiry Analysis
3.3.15.4. Pricing and Reimbursement Scenario
3.3.15.5. Indication Approved
3.3.15.6. Competitive Scenario
3.3.16. ZEPOSIA
3.3.16.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.16.2. Impact of Generics/Biosimilars
3.3.16.3. Patent Expiry Analysis
3.3.16.4. Pricing and Reimbursement Scenario
3.3.16.5. Indication Approved
3.3.16.6. Competitive Scenario
3.3.17. MAYZENT
3.3.17.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.17.2. Impact of Generics/Biosimilars
3.3.17.3. Patent Expiry Analysis
3.3.17.4. Pricing and Reimbursement Scenario
3.3.17.5. Indication Approved
3.3.17.6. Competitive Scenario
3.3.18. Lemtrada
3.3.18.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.18.2. Impact of Generics/Biosimilars
3.3.18.3. Patent Expiry Analysis
3.3.18.4. Pricing and Reimbursement Scenario
3.3.18.5. Indication Approved
3.3.18.6. Competitive Scenario
3.3.19. Acthar Gel
3.3.19.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.19.2. Competitive Scenario
3.3.19.3. Impact of Generics/Biosimilars
3.3.19.4. Patent Expiry Analysis
3.3.19.5. Pricing and Reimbursement Scenario
3.3.19.6. Indication Approved
3.3.19.7. Competitive Scenario
3.3.20. RAYOS
3.3.20.1. Market estimates and forecasts 2018 to 2030 (USD Million)
3.3.20.2. Impact of Generics/Biosimilars
3.3.20.3. Patent Expiry Analysis
3.3.20.4. Pricing and Reimbursement Scenario
3.3.20.5. Indication Approved
3.3.20.6. Competitive Scenario
Chapter 4. Top 20 Multiple Sclerosis Drugs Market: Regional Estimates & Trend Analysis
4.1. Regional Market Share Analysis, 2024 & 2030
4.2. Regional Market Dashboard
4.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
4.4. North America
4.4.1. North America Top 20 Multiple Sclerosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
4.4.2. U.S.
4.4.2.1. U.S. Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Canada
4.4.3.1. Canada Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Mexico
4.4.4.1. Mexico Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Europe
4.5.1. Europe Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. UK
4.5.2.1. Uk Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Germany
4.5.3.1. Germany Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. France
4.5.4.1. France Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. Italy
4.5.5.1. Italy Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.6. Spain
4.5.6.1. Spain Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.7. Denmark
4.5.7.1. Denmark Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.8. Sweden
4.5.8.1. Sweden Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.9. Norway
4.5.9.1. Norway Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Asia Pacific
4.6.1. Asia Pacific Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2. Japan
4.6.2.1. Japan Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3. China
4.6.3.1. China Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4. India
4.6.4.1. India Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.5. Australia
4.6.5.1. Australia Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.6. South Korea
4.6.6.1. South Korea Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.7. Thailand
4.6.7.1. Thailand Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Latin America
4.7.1. Latin America Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.2. Brazil
4.7.2.1. Japan Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.3. Argentina
4.7.3.1. China Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Middle East and Africa
4.8.1. Middle East and Africa Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2017 – 2030 (USD Million)
4.8.2. South Africa
4.8.2.1. South Africa Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.3. Saudi Arabia
4.8.3.1. Saudi Arabia Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.4. UAE
4.8.4.1. UAE Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.5. Kuwait
4.8.5.1. Kuwait Top 20 Multiple Sclerosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Multiple Sclerosis: Top 20 Drug Sales Market, by Region, 2018 - 2030 (USD Million)
Table 4 Global Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 5 Global Multiple Sclerosis: Top 20 Drug Sales Market, by Region, 2018 - 2030 (USD Million)
Table 6 North America Multiple Sclerosis: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 7 North America Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 8 U.S. Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 9 Canada Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 10 Mexico Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 11 Europe Multiple Sclerosis: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 12 Europe Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 13 UK Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 14 Germany Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 15 France Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 16 Italy Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 17 Spain Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 18 Norway Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 19 Sweden Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 20 Denmark Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 21 Asia-Pacific Multiple Sclerosis: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 22 Asia-Pacific Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 23 Japan Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 24 China Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 25 India Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 26 Australia Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 27 South Korea Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 28 Thailand Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 29 Latin America Multiple Sclerosis: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 30 Latin America Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 31 Brazil Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 32 Argentina Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 33 Middle East & Africa Multiple Sclerosis: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 34 Middle East & Africa Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 35 Saudi Arabia Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 36 UAE Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 37 Kuwait Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 38 South Africa Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 39 Rest of Middle East & Africa Multiple Sclerosis: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Multiple Sclerosis: Top 20 Drug Sales market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Market snapshot
Fig. 8 Application outlook (USD Million)
Fig. 9 Competitive landscape snapshot
Fig. 10 Market dynamics
Fig. 11 Porter’s five forces analysis
Fig. 12 PESTLE analysis
Fig. 13 Multiple Sclerosis: Top 20 Drug Sales market: Product outlook and key takeaways
Fig. 14 Multiple Sclerosis: Top 20 Drug Sales market: Product movement analysis
Fig. 15 OCREVUS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 TECFIDERA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 VUMERITY market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 AVONEX market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 PLEGRIDY market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 TYSABRI market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Top 20 multiple sclerosis drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 KESIMPTA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 GILENYA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 COPAXONE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 AUBAGIO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 MAVENCLAD market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Rebif market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 AMPYRA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 BETASERON market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 ZEPOSIA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 MAYZENT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Lemtrada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Acthar Gel market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 RAYOS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Multiple Sclerosis: Top 20 Drug Sales market revenue, by region, 2024 & 2030 (USD Billion)
Fig. 36 Regional marketplace: Key takeaways
Fig. 37 North America Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 38 Key country dynamics: North America
Fig. 39 U.S. Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 40 Canada Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 41 Mexico Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 42 Europe Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 43 Key country dynamics: Europe
Fig. 44 UK Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 45 Germany Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 46 France Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 47 Italy Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 48 Spain Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 49 Norway Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 50 Sweden Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 51 Denmark Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 52 Asia-Pacific Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 53 Key country dynamics: Asia-Pacific
Fig. 54 Japan Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 55 China Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 56 India Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 57 Australia Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 58 South Korea Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 59 Thailand Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 60 Rest of Asia-Pacific Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 61 Latin America Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 62 Key country dynamics: Latin America
Fig. 63 Brazil Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 64 Argentina Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 65 Rest of Latin America Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 66 Middle East & Africa (MEA) Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 67 Key country dynamics: MEA
Fig. 68 Saudi Arabia Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 69 UAE Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 70 Kuwait Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 71 South Africa Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 72 Rest of MEA Multiple Sclerosis: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 73 Company categorization
Fig. 74 Strategy mapping
Fig. 75 Company market position analysis
Fig. 76 Competitive landscape assessment
Fig. 77 Strategic framework analysis
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.